|
|
 |
|
Viewing report
|
|
|
|
Isis Pharmaceuticals, Inc.: SWOT Analysis & Company Profile
Business Review, April 2010, Pages: 23
Synopsis
Business Review’s Isis Pharmaceuticals, Inc. contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.
Summary
This SWOT Analysis company profile is a crucial resource for industry executives and anyone looking to quickly understand the key information concerning Isis Pharmaceuticals, Inc.’s business.
Business Review’s “Isis Pharmaceuticals, Inc. SWOT Analysis & Company Profile” reports utilize a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
Business Review strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about (Isis Pharmaceuticals, Inc.) for business intelligence requirements
- Studies and presents Isis Pharmaceuticals, Inc.’s strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
- The profile contains business operations, the company history, major products and services, prospects, key competitors, structure and key employees, locations and subsidiaries.
Reasons To Buy
- Quickly enhance your understanding of the company.
- Obtain details and analysis of the market and competitors as well as internal and external factors which could impact the industry.
- Increase business/sales activities by understanding your competitors’ businesses better.
- Recognize potential partnerships and suppliers.
- Obtain yearly profitability figures
Key Highlights
Isis Pharmaceuticals (ISIS) is a biopharmaceutical company engaged in the discovery and development of new class antisense drugs for the treatment of a broad range of diseases by using its patented ribonucleic acid (RNA)-based drug discovery technologies. The company has a pipeline of around 20 antisense drugs in clinical and preclinical development. The company is headquartered at Carlsbad, California, United States. On January 6, 2009, Isis Pharmaceuticals, Inc. sold its subsidiary Ibis Biosciences, Inc. to Abbott, for a closing purchase price of $175 million. In September 2009, Isis, Regulus and Alnylam reorted first microRNA patent grant in Japan. The Tuschl III patent covers miR-122, a liver-specific microRNA that has shown to facilitate replication of HCV infection.
|
|
|
|
